Day One Biopharmaceuticals, Inc. (DAWN) Reports Q2 Loss, Tops Revenue Estimates

Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of$0.67. This compares to loss of $0.61 per share a year ago. These figures are adjusted for non-recurring items. Day One Biopharmaceuticals, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of$8.19 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 810.22%. This compares to zero revenues a year ago. W ...